ライフサイエンスコーパス: MTCT

1 MTCT risk was elevated among women with incident infecti

2 ternal Ab responses may further reduce HIV-1 MTCT.

3 amplified env from plasma RNA for 19 HIV-1C MTCT pairs, 10 transmitting in utero (IU) and 9 transmit

4 HIV) through breast-feeding in a study of 59 MTCT cases and 116 controls nested within a cohort of an

5 effect of breast milk erythropoietin against MTCT.

6 ral responses that partially protect against MTCT of HIV is required to inform the development of a m

7 h weight (OR: 1.76; 95% CI: 1.07, 2.90), and MTCT of HIV by the time of birth (OR: 2.26; 95% CI: 1.18

8 death, low birth weight, preterm birth, and MTCT of HIV.

9 ncy/postpartum status and HIV incidence, and MTCT risk and rates.

10 creased risks of adverse infant outcomes and MTCT of HIV.

11 incidence of adverse pregnancy outcomes and MTCT of HIV.

12 endpoints were the safety of LdT/LAM use and MTCT rates.

13 We matched 59 incident breastfeeding MTCT cases to 59 nontransmitting controls based on the c

14 he risk of low efavirenz concentrations, but MTCT was rare.

15 In African cohorts, MTCT risk was significantly higher among women with inci

16 highly viremic mothers can further decrease MTCT of HBV.

17 be prioritized, and is critical to decrease MTCT.

18 an alternative strategy that would decrease MTCT of HBV.

19 Clinical trials to determine MTCT among breast-feeding women receiving HAART are need

20 receipt of nevirapine did not predict early MTCT in the BF group (P=.45).

21 Furthermore, children who escape MTCT are again at risk of infection when they become sex

22 regimens, with 2009 (56%) uptake, estimated MTCT risk would be 14.4% (Option A) or 13.4% (Option B).

23 method and analyzed the quasispecies of four MTCT pairs that broke through immunoprophylaxis.

24 to estimate the bottleneck effect during HBV MTCT, which provides information to optimize treatment f

25 um may serve as an initial mechanism for HIV MTCT.

26 potentially protect against breast milk HIV MTCT.

27 and HIV-1 loads in breast milk could improve MTCT prevention strategies.

28 r understanding of the genetic bottleneck in MTCT by revealing that viruses transmitted to infants ha

29 d <400 copies/mL, there was no difference in MTCT rate (0% without intravenous ZDV vs 0.6% with intra

30 hould be an important secondary end point in MTCT trials.

31 ARV treatment in MTCT potentially provides opportunities to better define

32 Maternal TB is associated with increased MTCT of HIV.

33 decanoic acid were associated with increased MTCT, whereas trans FAs were related to higher CAV and C

34 Intrapartum MTCT was associated with placental microtransfusions.

35 y in an infant macaque model for intrapartum MTCT.

36 , comparison of env sequences from NT and IU MTCT participants indicated statistically significant di

37 n addition, viral sequences isolated from IU MTCT placental tissue showed variation in env V1 loop le

38 of the eight NT cases and six of the nine IU MTCT cases.

39 ng in utero mother-to-child transmission (IU MTCT), transmitted viral variants must pass through mult

40 opathy differences in Env associated with IU MTCT alter viral cellular tropism or affinity, allowing

41 547 infants in the BF group at risk for late MTCT, 24 (4.4%) were infected.

42 001) and breast milk (P<.001) predicted late MTCT.

43 ional PMTCT Program led to a projected 12-mo MTCT risk of 20.3%.

44 k (95% confidence interval [CI], 2%-120%) of MTCT of HIV at 6 weeks, a 2-fold higher risk of MTCT of

45 lk exposure to HIV accounts for up to 44% of MTCT.

46 lk exposure to HIV accounts for up to 44% of MTCT.

47 There was 1 case of MTCT.

48 tion of viral quasispecies in the context of MTCT.

49 opment of new options for the elimination of MTCT as well as policy changes that may help the current

50 Unique features of MTCT and paediatric HIV disease could be helpful in unde

51 mize treatment for reducing the frequency of MTCT.

52 The rapidly increasing incidence of MTCT worldwide has resulted in an urgent need for preven

53 eview, we discuss the proposed mechanisms of MTCT, evidence for cell-free and cell-associated transmi

54 There was an increased odds of MTCT for every log2 increase in maternal sCD14 concentra

55 In all four pairs of MTCT samples, we consistently observed a significant ove

56 We investigated uptake of prevention of MTCT (PMTCT) services, infant feeding recommendations, a

57 viral therapy (HAART) used for prevention of MTCT (PMTCT).

58 V nAbs are associated with the prevention of MTCT of HCV.

59 BV epidemic will need improved prevention of MTCT.

60 re was no apparent difference in the rate of MTCT among women with subtype A versus D (adjusted odds

61 Outcomes of interest were reduction of MTCT and adverse outcomes to mothers and newborns.

62 maternal plasma predicted a reduced risk of MTCT and mediated autologous virus neutralization, sugge

63 T of HIV at 6 weeks, a 2-fold higher risk of MTCT of HIV through breast-feeding among children who we

64 The risk of MTCT of HIV-1 was comparable with these regimens.

65 tivation may adversely influence the risk of MTCT of HIV.

66 s of maternal HIV disease stage, the risk of MTCT was inversely related to 11c,14c-eicosadienoic acid

67 The risk of MTCT was inversely related to breast milk erythropoietin

68 to parasitic antigens increases the risk of MTCT, cord blood mononuclear cells (CBMCs) from Kenyan a

69 FAs in breast milk might reduce the risk of MTCT.

70 envelope was predictive of a reduced risk of MTCT.

71 through 12 months after delivery on risk of MTCT.

72 priming to malaria may increase the risk of MTCT.

73 sociated transmission in different routes of MTCT, and the impact of ARVs on virus levels and transmi

74 al/neonatal vitamin A supplementation has on MTCT, HIV-free survival, and mortality in HIV-exposed in

75 th viral load >/=1000 copies/mL, the overall MTCT rate was higher without than with intravenous ZDV (

76 significant progress in reducing peripartum MTCT of HIV with ART, continued access to ART throughout

77 lementation significantly affected postnatal MTCT or overall mortality between baseline and 24 months

78 have suggested that prevention of postnatal MTCT may require both Env-specific IgA and functional Ig

79 ded, alternative means are needed to prevent MTCT of HIV.

80 ssment of prophylactic programmes to prevent MTCT, including child mortality and infection averted.

81 ogen design for maternal vaccines to prevent MTCT.IMPORTANCE Efforts to curb HIV-1 transmission in pe

82 ine versus single-dose nevirapine, to reduce MTCT of HIV among breast-fed infants.

83 Antiviral therapy reduced MTCT, as defined by infant hepatitis B surface antigen s

84 therapy improves HBV suppression and reduces MTCT in women with chronic HBV infection with high viral

85 ic mothers was equally effective in reducing MTCT.

86 ines the relationship between HIV-1 subtype, MTCT, and the development of Nvp resistance (Nvp(R)) in

87 Our findings suggest that MTCT risk is associated with neutralizing maternal IgG t

88 t target of the host immune response, in the MTCT bottleneck.

89 treatment are challenges for preventing the MTCT.

90 ng hepatitis B mother-to-child transmission (MTCT) in real-world settings.

91 ven randomised mother-to-child transmission (MTCT) intervention trials, we estimate mortality in Afri

92 Mother-to-child transmission (MTCT) of HBV remains an important source of incident cas

93 reased risk of mother-to-child transmission (MTCT) of HCV, HCV nAb titers were assessed in 63 mothers

94 Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) is a major route of HBV

95 Perinatal or mother-to-child transmission (MTCT) of hepatitis B virus (HBV) remains the major risk

96 noprophylaxis, mother-to-child transmission (MTCT) of Hepatitis B Virus still occurs in approximately

97 ssociated with mother-to-child transmission (MTCT) of HIV and other adverse pregnancy outcomes.

98 th the risk of mother-to-child transmission (MTCT) of HIV by breastfeeding and with shedding of cell-

99 Prevention of mother-to-child transmission (MTCT) of HIV remains a major objective where antenatal c

100 th the risk of mother-to-child transmission (MTCT) of HIV, we nested a case-control study (49 pairs o

101 Mother-to-child transmission (MTCT) of HIV-1 has been associated with symptomatic and

102 e mechanism of mother-to-child transmission (MTCT) of HIV-1 is not well described.

103 Mother-to-child transmission (MTCT) of HIV-1 is the major mode of paediatric infection

104 erefore reduce mother-to-child transmission (MTCT) of HIV-1 via breast-feeding.

105 tes of risk of mother-to-child transmission (MTCT) of HIV-1, including responses associated with prot

106 prevention of mother-to-child transmission (MTCT) of HIV-1.

107 ssociated with mother-to-child transmission (MTCT) of HIV; the role of maternal tuberculosis (TB), ho

108 egimens reduce mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) but result i

109 Mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) continues to

110 prevention of mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) in high-reso

111 nd the risk of mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) through brea

112 sk factors for mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) via breast-f

113 ing peripartum mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV) with antiret

114 ancy outcomes, mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV), and child m

115 isk factor for mother-to-child transmission (MTCT) of human immunodeficiency virus (HIV).

116 for preventing mother-to-child transmission (MTCT) of human immunodeficiency virus type 1 (HIV-1).

117 quired through mother-to-child transmission (MTCT) or failed chemoprophylaxis populates viral reservo

118 testing, and a mother-to-child transmission (MTCT) rate at 12 months of 4.9%; we simulated guideline-

119 outcomes, and mother-to-child transmission (MTCT) risk.

120 route is rare, mother-to-child transmission (MTCT) through the neonatal/infant oral and/or gastrointe

121 f new cases of mother-to-child transmission (MTCT), and yet there are limited data on HIV-1C transmis

122 minants of HIV mother-to-child transmission (MTCT).

123 into risks of mother to child transmission (MTCT).

124 ostnatal HIV-1 mother-to-child transmission (MTCT).

125 Mother-to-child-transmission (MTCT) of human immunodeficiency virus (HIV) remains a si

126 ed low risk of mother-to-child-transmission (MTCT) was dependent on the C-terminal flank of the V3 cr

127 to compare mother-to-child HIV transmission (MTCT) risk among women with incident versus chronic infe

128 ric HIV: a mother-to-child HIV transmission (MTCT) risk of less than 5%.

129 s among placental microtransfusion, in-utero MTCT, maternal immunosuppression, and poor birth outcome

130 o eradication of incident HBV infections via MTCT include underutilization of immunoprophylaxis with

131 The primary model outcome was MTCT risk at weaning.

132 ow-income and middle-income countries, where MTCT is common, because of difficulty obtaining and deli

133 ional age, and birth weight) associated with MTCT of HIV.

134 venous ZDV and compared its association with MTCT rate and other infant parameters, according to vari

135 thout confirmatory testing, in settings with MTCT rates similar to that of South Africa, more than 10

136 breastfeeding duration were shortened, would MTCT risks at 95% uptake fall below 5%.